Annales de cardiologie et d'angeiologie最新文献

{"title":"Effect of neighborhood socioeconomic status on smoking behavior in the CARVAR 92 cohort study","authors":"Hélène Hergault ,&nbsp;Diane Mansencal ,&nbsp;Alain Beauchet ,&nbsp;Loïc Josseran ,&nbsp;Thomas Lévesque ,&nbsp;Pierre Boisson de Chazournes ,&nbsp;Orianne Weizman ,&nbsp;Abdallah Fayssoil ,&nbsp;Marion Pépin ,&nbsp;Christophe Rodon ,&nbsp;Olivier Dubourg ,&nbsp;Nicolas Mansencal ,&nbsp;Marie Hauguel-Moreau","doi":"10.1016/j.ancard.2025.101956","DOIUrl":"10.1016/j.ancard.2025.101956","url":null,"abstract":"<div><h3>Background</h3><div>Tobacco is one of the strongest modifiable cardiovascular risk factors, contributing significantly to cardiovascular morbidity and mortality. We aimed to assess the impact of neighborhood deprivation on smoking status and smoking intensity.</div></div><div><h3>Methods</h3><div>Between 2010 and 2018, we studied smoking status and intensity in 7821 participants residing in Paris west suburb included in the CARVAR 92 prospective cohort. Moderate or high-intensity smoking was defined as consuming more than 10 cigarettes a day Three neighborhood clusters of decreasing socioeconomic status (SES) were obtained after a hierarchical clustering analysis applied to eighteen measures of SES. We used multivariate logistic models to estimate the association between neighborhood SES (NSES) clusters and smoking status and intensity.</div></div><div><h3>Results</h3><div>Of the 7821 participants (mean age: 55.1 ± 9.7 years, 56.8% women), 16.4% were smokers (N=1284): 18.8% of males (N=635) and 14.6% of females (N=649, p &lt; 0.0001). The overall proportions of smokers were similar in the three groups: 16.2%, 15.6% and 18.2% in high, medium, and low NSES, respectively (p for trend=0.171). We observed a higher proportion of males among smokers in each NSES: 17.6%, 20.1% and 20.2% (p for trend=0.03) in high, medium and low NSES, respectively, versus 15.2%, 12.3%, and 15.9% (p for trend=0.801) among women. Lowest SES neighborhood was independently associated with moderate or high-intensity smoking in the whole population (OR=1.66; 95% CI 1.27-2.04, p = 0.02), in men (OR 1.59, 95% CI 1.06-2.40), and in women (OR 1.79, 95% CI 1.17-2.72).</div></div><div><h3>Conclusion</h3><div>In conclusion, the intensity of smoking is greatly influenced by neighborhood SES. We found an association between lowest SES neighborhoods and moderate or high-intensity smoking, regardless of sex, with a slightly more pronounced effect among women.</div></div>","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 6","pages":"Article 101956"},"PeriodicalIF":0.3,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time in therapeutic range in venous thromboembolism : Role in preventing complications","authors":"Imène Rachdi,&nbsp;Mariem Ben Brahim,&nbsp;Mehdi Somai,&nbsp;Ibrahim Arbaoui,&nbsp;Besma Ben Dhaou,&nbsp;Fatma Boussema,&nbsp;Fatma Daoud,&nbsp;Zohra Aydi","doi":"10.1016/j.ancard.2025.101958","DOIUrl":"10.1016/j.ancard.2025.101958","url":null,"abstract":"<div><h3>Background</h3><div>Vitamin K antagonists (VKAs) are the most commonly prescribed drug for the treatment of venous thromboembolism (VTE). Our study’s aim was to evaluate the role of Time in Therapeutic Range (TTR) in preventing thrombotic and hemorrhagic complications in patients treated by VKAs for VTE.</div></div><div><h3>Methods</h3><div>Our study is prospective, descriptive, and longitudinal, including patients admitted to an Internal Medicine department in Tunis, during a 9-month period. One hundred patients diagnosed with VTE confirmed with imaging and treated with VKAs were included. TTR was calculated using Rosendaal’s method through a free software <em>INR</em> PRO<em>©</em>.</div></div><div><h3>Results</h3><div>The mean age of patients was 59.4 ± 16.7 years. Sex-ratio was 1.5. VKAs were mainly prescribed for deep venous thromboses (57%). Cancer was the most common etiology (26%). The mean follow-up period was 5.3 months. The mean TTR was 36.1±22.5%. Twenty-seven percent of patients had a TTR&gt;50%. We noted 25% of hemorrhagic events and 15% of thromboembolic recurrence. A TTR&lt;50% was correlated with hemorrhagic complications (<em>p</em>=0.02), but not with thrombotic ones (<em>p</em> = 0.224).</div></div><div><h3>Conclusion</h3><div>Our results outline the necessity of implementing adequate tools to improve anticoagulation in our population. Implementing TTR as a quality assessment tool for anticoagulation will likely decrease complications related to VKAs.</div></div>","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 6","pages":"Article 101958"},"PeriodicalIF":0.3,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infarctus du myocarde inférieur avec extension au ventricule droit lié à un énorme thrombus naissant de l’aorte ascendante et envahissant la coronaire droite – cas clinique","authors":"H. Bensussan ,&nbsp;R. Auger ,&nbsp;T. Genet ,&nbsp;A. Bernard","doi":"10.1016/j.ancard.2025.101959","DOIUrl":"10.1016/j.ancard.2025.101959","url":null,"abstract":"<div><div>This case report tells the story of a non-trivial infarction, where the usual rapid management of a ST-segment elevation infarction could have led to serious consequences for the patient. It is important to maintain a systematic clinical assessment before performing invasive procedures.</div></div>","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 6","pages":"Article 101959"},"PeriodicalIF":0.3,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145386023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboembolic complications following rituximab therapy in a patient with bullous pemphigoid : A case report","authors":"Nouhaila Wakil,&nbsp;Lamia Tlohi,&nbsp;Meryem Haboub,&nbsp;Rachida Habbal","doi":"10.1016/j.ancard.2025.101957","DOIUrl":"10.1016/j.ancard.2025.101957","url":null,"abstract":"<div><div>Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular mortality worldwide, following stroke and myocardial infarction. Rituximab, a monoclonal antibody targeting CD20 on B lymphocytes, is increasingly used in the management of autoimmune conditions. While generally well tolerated, rare thromboembolic events have been reported. The pathophysiological mechanisms remain unclear but may involve endothelial dysfunction, cytokine release, or immune-mediated vascular injury.</div><div>We report the case of a 56-year-old woman with bullous pemphigoid treated with rituximab, who developed extensive thromboembolic complications. The patient presented with acute dyspnea and leg pain. Clinical evaluation and imaging confirmed the diagnosis of DVT and PE. No predisposing factors such as recent surgery, immobilization, or malignancy were identified. The temporal relationship with rituximab infusion suggested a possible causal link. Anticoagulation was initiated, and rituximab therapy was discontinued. The aim of this report is to underscore the possible thromboembolic risk related to rituximab, and to discuss the underlying pathophysiological mechanisms, contributing risk factors, and strategies for prevention and clinical management.</div></div>","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 6","pages":"Article 101957"},"PeriodicalIF":0.3,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145386017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of Post-ACS Management in France: National Consensus Outcomes from the EuroPath II Initiative","authors":"Marc Villaceque ,&nbsp;Cyrille Bergerot ,&nbsp;François Schiele ,&nbsp;Pierre Sabouret ,&nbsp;Chaimae Ighidi ,&nbsp;Franck Boccara ,&nbsp;Jean Ferrières ,&nbsp;Meyer Elbaz ,&nbsp;Adrien Lemaitre","doi":"10.1016/j.ancard.2025.101969","DOIUrl":"10.1016/j.ancard.2025.101969","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The in-hospital management of acute coronary syndrome (ACS) is clearly established; however, post discharge, ACS patients face significant challenges including securing timely follow-up appointments, managing complex medication regimens, and maintaining long-term adherence to lifestyle changes while lacking adequate psychological support. A national Delphi consensus process was conducted to assess post-ACS management practices in France. This involved administration of a structured questionnaire to a panel of experts, aiming to evaluate current clinical practices and establish a unified approach.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The outcomes of the national consensus on post-ACS management were developed with the collective clinical expertise and real-world experience of a panel of French cardiologists. A two-day national face-to-face expert board was convened to identify challenges in post-ACS management and collaboratively develop solutions aimed at harmonizing clinical practices across France. Building upon the insights gathered during this board, a structured national survey was subsequently distributed to assess and further standardize these practices nationwide.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A comprehensive post-ACS checklist proposes a structured pathway integrating hospital discharge protocols, scheduled follow-up appointments, secondary prevention treatments, rehabilitation planning, and a standardized discharge document for transmitting comprehensive patient information to ensure safe discharge from hospital. The European Society of Cardiology (ESC) guidelines for post-ACS care pathway management include in-hospital empowerment consultation by cardiologists and specialized nurses, scheduled appointments (4–6 weeks and 1-year with a cardiologist), intermediate follow-ups through calls or visits, cardiac rehabilitation planning, and coordinated communication among healthcare providers (utilizing digital tools and trained networks) to maintain consistent prevention messaging and enhance patient adherence. To warrant 100% review of post-ACS patients within 6 weeks post discharge, coordinated discharge planning, mandatory training for healthcare correspondents, streamlined appointment scheduling, patient education, and media engagement to facilitate effective follow-up care are necessary. The first post-ACS consultation encompasses a comprehensive approach, including disease history review, risk factor assessment, determination of the extent of coronary disease via angiography, clinical and laboratory evaluations, treatment optimization, lifestyle counseling, patient education on warning signs, psychosocial support, cardiac rehabilitation options, and follow-up planning, aimed at reducing recurrence risk and ensuring optimal patient care. The ESC guidelines-based personalized approach for medication management between 1 and 12 months includes antiplatelet treatment (intensity modulated by selecting a p","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 5","pages":"Article 101969"},"PeriodicalIF":0.3,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Observational Evidence in Geriatric Patients AGING-HF","authors":"A. Hacil MD ,&nbsp;Y. Antakly-Hanon MD ,&nbsp;A. Lacour MD ,&nbsp;J.P. David MD, PhD ,&nbsp;T. Khalifa MD ,&nbsp;M. Piccoli MD ,&nbsp;A. clemencin MD ,&nbsp;P. Assayag MD, PhD ,&nbsp;J.S. Vidal MD, PhD ,&nbsp;O. Hanon MD, PhD","doi":"10.1016/j.ancard.2025.101961","DOIUrl":"10.1016/j.ancard.2025.101961","url":null,"abstract":"<div><h3>Contexte</h3><div>Les inhibiteurs du cotransporteur sodium-glucose de type 2 (iSGLT2) ont montré des effets bénéfiques dans la prise en charge de l'insuffisance cardiaque (IC), mais les données concernant leur utilisation chez les populations gériatriques à forte comorbidité restent limitées. Cette étude observationnelle avait pour but d’évaluer l’efficacité et la tolérance des iSGLT2 en conditions réelles chez des patients âgés atteints d’IC.</div></div><div><h3>Méthodes</h3><div>Cette étude prospective multicentrique a inclus 496 patients hospitalisés pour insuffisance cardiaque aiguë (ICA) dans trois unités gériatriques. L'âge moyen était de 90 ans, avec un score moyen de comorbidité de Charlson de 8,2. Les participants ont été répartis en deux groupes: le groupe iSGLT2 (n=260), recevant de l’empagliflozine ou de la dapagliflozine en complément du traitement standard de l’IC, et le groupe contrôle (n=236), recevant uniquement le traitement standard. Les critères de jugement principaux étaient la mortalité toutes causes confondues, les réhospitalisations pour IC, et les événements indésirables sur un an.</div></div><div><h3>Résultats</h3><div>L’utilisation des iSGLT2 était associée à une réduction du risque de mortalité toutes causes confondues (HR 0,67 [IC 95%: 0,46–0,98], p = 0,031), de réhospitalisation pour IC (HR 0,64 [IC 95%: 0,42–0,97], p = 0,037), et du critère combiné (HR 0,60 [IC 95%: 0,44–0,82], p = 0,001) à un an, après ajustement multivarié. Aucune interaction significative n’a été observée entre la fraction d'éjection du ventricule gauche et l'utilisation des iSGLT2 (p pour interaction = 0,12). Bien que les infections urinaires et génitales aient été rapportées plus fréquemment dans le groupe iSGLT2, le taux d’arrêt du traitement est resté faible (2,7%).</div></div><div><h3>Conclusion</h3><div>Chez cette population très âgée et à forte comorbidité, le traitement par iSGLT2 était associé à une réduction significative de la mortalité et des réhospitalisations pour IC, avec une bonne tolérance et un profil de sécurité acceptable.</div></div>","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 5","pages":"Article 101961"},"PeriodicalIF":0.3,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0003-3928(25)00113-1","DOIUrl":"10.1016/S0003-3928(25)00113-1","url":null,"abstract":"","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 5","pages":"Article 101974"},"PeriodicalIF":0.3,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Une CVDA pas comme les autres","authors":"S. DUDAY,&nbsp;T. WAJCHERT","doi":"10.1016/j.ancard.2025.101967","DOIUrl":"10.1016/j.ancard.2025.101967","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Un homme de 46 ans qui a pour seul antécédent une spondylarthrite ankylosante avec sacro-iliite consulte en cardiologie pour une dyspnée d’effort depuis 4 mois. Ce tableau révèle après échographie cardiaque et angioscanner thoracique une dilatation et une dysfonction du ventricule droit (VD) sans embolie pulmonaire. L’ECG met en évidence une onde epsilon et un aspect de bloc de branche droit incomplet (BBD) avec ondes T négatives de V1 à V4. La télémétrie montre des épisodes de tachycardies ventriculaires non soutenus. La coronarographie est normale. Le cathétérisme droit ne montre pas d’hypertension pulmonaire et l’angiographie du VD montre un aspect en pile d’assiettes. L’IRM cardiaque montre des zones dyskinétiques et anévrismales du VD avec des plages de rehaussements tardifs ventriculaires gauche et droite ainsi qu’un thrombus intra-VD. On note également la présence d’une dysfonction systolique du ventricule gauche (FEVG à 35%).&lt;/div&gt;&lt;div&gt;Alors que le diagnostic de cardiomyopathie arythmogène du ventricule droit (CVDA) est en train d’être posé devant 3 critères majeurs et 2 mineurs de la Task-Force&lt;span&gt;&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;, on note cependant plusieurs atypies dans le dossier. Premièrement, les troubles du rythme ventriculaire s’associent à des troubles de conductions (BAV 1 et BAV2 Mobitz 2 à la télémétrie). Deuxièmement, en IRM la paroi du VD n’est pas amincie et il existe un important œdème septal. Enfin, il n’existe pas d’antécédents familiaux de cardiomyopathies.&lt;/div&gt;&lt;div&gt;L’ensemble de ces éléments peuvent alors faire suspecter une sarcoïdose cardiaque.&lt;/div&gt;&lt;div&gt;Le bilan extracardiaque de la sarcoïdose met uniquement en évidence des épaississements de septa interlobulaires, et un antécédent de sacro-iliite qui bien que décrite dans les sarcoïdoses, n’est pas typique&lt;span&gt;&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;. En revanche le PET-TDM met en évidence un hypermétabolisme diffus du VD, du septum et de la paroi inférieure, sans autre hypermétabolisme associé. La biopsie endomyocardique confirme la présence de granulomes épithélioïdes gigantocellulaires sans nécrose caséeuse, et donc le diagnostic de sarcoïdose. Le patient a été par la suite implanté d’un défibrillateur implantable et traité par méthotrexate et corticothérapie.&lt;/div&gt;&lt;div&gt;La CVDA et la sarcoïdose cardiaque sont des pathologies pouvant être difficiles à distinguer car elles peuvent remplir toutes les deux les critères diagnostiques de la Task-Force. Toutefois comparée à la CVDA, la sarcoïdose cardiaque se révèle à un âge plus tardif (45 ans d’âge médian au diagnostic 29 ans), il n’existe pas d’histoire familiale, et est plus souvent associée à des troubles de conductions, à une dysfonction VG et à un rehaussement tardif en IRM dans le septum, comme chez notre patient&lt;span&gt;&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;. De plus, notre patient ne présentait pas d’atteinte extracardiaque évocatrice de sarcoïdose, renforçant la difficulté du diagnostic.&lt;/div&gt;&lt;div&gt;S’il faut effe","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 5","pages":"Article 101967"},"PeriodicalIF":0.3,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effets de la pleine conscience (MBSR) sur la santé cardiométabolique: revue systématique et méta-analyse de 1200 participants","authors":"M. Temgoua ,&nbsp;F. Teddy Endomba ,&nbsp;C. Berenfeld ,&nbsp;A. Berenfeld ,&nbsp;J.G. Bloch","doi":"10.1016/j.ancard.2025.101963","DOIUrl":"10.1016/j.ancard.2025.101963","url":null,"abstract":"<div><h3>Contexte</h3><div>La réduction du stress basée sur la pleine conscience (<em>Mindfulness-Based Stress Reduction, MBSR)</em> est proposée comme approche complémentaire pour améliorer les issues liées au stress et réduire le risque cardiovasculaire.</div></div><div><h3>Méthodes</h3><div>Nous avons réalisé une revue systématique et une méta-analyse pour évaluer l’impact de la stratégie MBSR sur la santé cardiométabolique. Les essais contrôlés évaluant les effets de la MBSR sur les facteurs de risque cardiométaboliques et les événements cliniques ont été inclus. Une recherche exhaustive a été menée dans les bases de données PubMed, EMBASE, Cochrane Library, Web of Science et PsycINFO. Le risque de biais a été évalué à l’aide de l’outil RoB2, et une méta-analyse à effets aléatoires a été réalisée. Le biais de publication a été examiné à l’aide <em>du Funnel plot</em> et du test d'Egger.</div></div><div><h3>Résultats</h3><div>Quatorze études (n ≈ 1 200 participants) ont été incluses. La stratégie MBSR était associée à des réductions significatives de l’hémoglobine glyquée (HbA1c), de la pression artérielle systolique, du stress perçu et des symptômes dépressifs. Le biais de publication était peu probable pour la majorité des critères évalués, et la certitude globale des preuves variait de faible à élevée (fig. 1 à 7).</div></div><div><h3>Conclusion</h3><div>Ces résultats suggèrent que la stratégie MBSR pourrait constituer une intervention complémentaire efficace pour réduire le risque cardiométabolique et améliorer le bien-être psychologique. Des essais randomisés de qualité supérieure sont nécessaires pour confirmer ces résultats.</div></div>","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 5","pages":"Article 101963"},"PeriodicalIF":0.3,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial board / Ours rédaction","authors":"","doi":"10.1016/S0003-3928(25)00111-8","DOIUrl":"10.1016/S0003-3928(25)00111-8","url":null,"abstract":"","PeriodicalId":7899,"journal":{"name":"Annales de cardiologie et d'angeiologie","volume":"74 5","pages":"Article 101972"},"PeriodicalIF":0.3,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}